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Malignant hyperthermia (MH) is an anesthetic-drug–induced, life-threatening hypermetabolic syndrome caused by
abnormal calcium regulation in skeletal muscle. Often inherited as an autosomal dominant trait, MH has linkage
to 30 different mutations in the RYR1 gene, which encodes a calcium-release–channel protein found in the sar-
coplasmic reticulum membrane in skeletal muscle. All published RYR1 mutations exclusively represent single-
nucleotide changes. The present report documents, in exon 44 of RYR1 in two unrelated, MH-susceptible families,
a 3-bp deletion that results in deletion of a conserved glutamic acid at position 2347. This is the first deletion, in
RYR1, found to be associated with MH susceptibility. MH susceptibility was confirmed among some family members
by in vitro diagnostic pharmacological contracture testing of biopsied skeletal muscle. Although a single-amino-
acid deletion appears to be a subtle change in the protein, the deletion of Glu2347 from RYR1 produces an unusually
large electrically evoked contraction tension in MH-positive individuals, suggesting that this deletion produces an
alteration in skeletal-muscle calcium regulation, even in the absence of pharmacological agents.
Malignant hyperthermia (MH [MIM 145600]) is often
inherited as an autosomal dominant pharmacogenetic
trait that predisposes individuals to a life-threatening an-
esthetic-drug–induced hypermetabolic syndrome (Nelson
and Flewellen 1983). A family’s predisposition to MH is
identified by a clinical episode of MH in the proband,
and other family members can be screened by in vitro
pharmacological contracture testing of biopsied skeletal
muscle (Larach 1989). The pathobiology of MH is an
abnormal increase in myoplasmic [Ca], caused by vol-
atile anesthetics and by depolarizing muscle relaxants.
Unabated, this rise in [Ca] stimulates metabolic and
contracture events that ultimately create acid/base and
electrolyte disturbances, causing cell destruction and
death. The occurrence of MH in species other than hu-
mans has provided investigational animal models that
have advanced our knowledge about this disease. Mis-
sense mutations in the gene encoding the skeletal-muscle
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ryanodine receptor, RYR1 (MIM 180901), have been
linked to MH in the animal models for the pig
(Gly614Arg [Fujii et al. 1991]) and for the dog
(Val547Ala [Roberts et al., in press]) (also see GenBank).
The search for similar mutations in MH-susceptible hu-
man families has presently led to the discovery of 30 RYR1
missense mutations associated with MH in ∼50% of af-
fected families (Brown et al. 2000; Chamley et al. 2000;
Jurkat-Rott et al. 2000; McCarty et al. 2000; Monnier
et al. 2000; Sambuughin et al., in press-a, in press-b). All
RYR1 mutations associated with MH are missense mu-
tations, and we now report the first deletion of a single
amino acid, in RYR1, cosegregating with MH, as well as
its expression in two unrelated MH-affected families.
The North American MH diagnostic protocol (Larach
1989; Allen et al. 1998) was utilized for the in vitro
skeletal-muscle–contracture tests. Subjects referred to
our MH diagnostic center are administered MH-non-
trigger anesthesia, and fascicles of the vastus lateralis are
taken and mounted in vitro in muscle-contracture cham-
bers for testing. A different set of three fascicles are used
for each of two tests. The first test exposes the fascicles
to 3% halothane, and the second test exposes the muscle
to increasing concentrations of caffeine, starting at a
concentration of 0.5 mM and ending at a concentration
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Table 1














Individual 3 .7 .07 12.8
Individual 4 5.8 1.69 24.6
Family 2:
Individual 3 2.5 .52 29.1
Individual 4 3.9 2.2 19.2
NOTE.—Tension value represents the maximum response among
three fascicles tested, for each variable.
Figure 1 A, Sequence analysis of cloned PCR product, revealing
a 3-bp deletion (GGA). The upper chromatogram shows a sequence
of DNA, from the proband in family 1, with the deletion. The arrow
indicates the site of the deletion. The lower chromatogram shows a
sequence of DNA, from individual 1 in family 2, without the deletion.
B, Amino acid comparison of RYR1 region flanking the deleted residue.
The asterisk (*) indicates glutamic acid (E) deleted at 2347.
of 32 mM. A contracture response of 0.7 g to 3%
halothane or 0.3 g at caffeine concentrations of 2
mM, in one or more fascicles, is sufficient for an MH-
positive diagnosis.
Family 1 is represented by a proband who developed
life-threatening signs of MH when, at 9 years of age, she
was anesthetized for a tonsillectomy. Anesthesia was in-
duced with thiopental sodium and was maintained with
halothane. On injection of succinylcholine (20 mg iv) to
facilitate intubation of the trachea, the patient developed
global skeletal-muscle rigidity, and the mouth could not
be opened. The body temperature rose from 37C to
40.3C over a period of 20 min. No data regarding blood
gases, end-tidal carbon dioxide, or other metabolic in-
dicators were available. The proband was administered
fluids, recovered without sequelae, and received a clinical
diagnosis of MH positive. In 1980, the proband under-
went a muscle biopsy to test for calcium uptake and for
actomyosin ATPase activity in thin section (Allen et al.
1986). These tests for MH were subsequently discontin-
ued because of reliability problems, but in this proband
the results were reported as “unquestionably positive.”
Two of the proband’s three brothers underwent muscle
biopsies to test for MH-diagnostic contracture, and both
had unequivocally MH-positive contracture responses to
caffeine and to halothane (table 1). Part of the in vitro
MH muscle-contracture protocol involves optimizing the
length of muscle fascicles to obtain maximum electrically
evoked contraction tension. We observed unusually large
contraction tensions in the muscle fascicles of these two
individuals (table 1).
Family 2 is represented by a proband who developed
signs of MH when, at 15 years of age, she was anes-
thetized for maxillary-mandibular advancement–aug-
mentation genioplasty. Anesthesia was induced with
propofol (140 mg) and fentanyl (3.5 mg), and nasotra-
cheal intubation was accomplished after topical appli-
cation of lidocaine; anesthesia was maintained with iso-
flurane. During the first 60 min after induction of
anesthesia, no signs of MH were evident. For the period
of 60–150 min after induction of anesthesia, elevations
in end-tidal carbon dioxide (70 mmHg maximum) and
in body temperature (38.9C maximum) were associated
with an arterial-blood acidosis (pH 7.22, pCO2 53, and
pO2 414) and base deficit (5.4). A clinical diagnosis
of MH was made, and an MH treatment protocol, in-
cluding dantrolene administration, was instituted. The
signs of MH reversed during the next 40 min, and the
proband survived without sequelae. The proband and
her sister subsequently underwent muscle biopsies, and
each had unequivocally MH-positive in vitro contracture
responses to caffeine and to halothane (table 1). Ab-
normally large electrically evoked in vitro contraction
tensions were also observed in muscle of the proband
and of her sister (table 1).
Genetic screening was performed on exons 39–46 of
RYR1, in both probands, since 150% of MH-associated
RYR1 mutations occur within this region. When the
SSCP screening method was used, a unique but similar
pattern of single-strand DNA was detected in the pro-
bands, and this occurred within a PCR product from
exon 44. PCR was performed with primers RYR44F (5′-
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Figure 2 Pedigrees of two families with MH-positive-plus phenotype. Blackened circles and squares denote patients who had either a
clinical episode of MH or positive muscle-biopsy contracture-test results; the unblackened empty circle denotes a family member who was not
studied; circles and square with a question mark denote family members studied genetically but in whom contracture testing was not performed;
arrows indicate the probands. Haplotypes were constructed on the basis of the markers, with the following order: D20S220 (top), an intragenic
TaqI polymorphism in RYR1 exon 20, presence (a) or absence (A) of the deletion, and D20S47. Segregation of the deletion was analyzed by
BseRI digestion of a 252-bp PCR product of exon 44, as shown on the agarose gel below the pedigrees. The deletion was detected by loss of
a BseRI site, resulting in the generation of 252-bp, 173-bp, and 79-bp DNA fragments. The first lane on the left represents a 100-bp marker
ladder.
gggaggtctctgatggtg-3′) and RYR44R (5′-cgggagactcactg-
ctcg-3′), by use of MasterAmp 2X PCR Premix D (Epi-
centre Technologies), for 1 cycle of 94C for 3 min and
35 cycles of 94C for 30 s, 58C for 30 s, and 72C for
30 s (for RYR1 exon 44 sequence, see GenBank). Direct
sequencing of PCR product from the probands was per-
formed by use of a QIAquick PCR purification kit (Qia-
gen) and a BigDye Terminator Cycle Sequencing Kit
(ABI). The sequence alterations in exon 44 were de-
tected, in both probands, as overlapping nucleotides,
which indicate either a deletion or an insertion mutation
type. To ensure the nature and the location of the se-
quence alteration, we cloned PCR product, using a
TOPO TA cloning kit (Invitrogen), and sequenced 10
clones for each proband. As shown in figure 1A, se-
quencing of cloned PCR product revealed a deletion of
GGA nucleotides in exon 44. Surprisingly, the type and
the location of the deletion were the same in all MH-
positive members of both families (fig. 1A). This deletion
leads to an in-frame loss, at position 2347, of glutamic
acid, an amino acid that is conserved in RYR1 across
different species (fig. 1B). The deletion eliminates a re-
striction site for the enzyme BseRI, which allows for
detection by restriction-enzyme analysis. DNA obtained
from the members of both families was screened for the
deletion, and figure 2 shows the results for the two ped-
igrees. All four members of the two families who were
diagnosed as MH-positive by in vitro contracture test
each had a deletion (fig. 2).
Since a deletion has never been reported in RYR1 and
since both probands were referred to the same MH di-
agnostic center, we investigated the possibility that these
two families are related, and we genotyped some mem-
bers of these two families by using additional genetic
markers—TaqI polymorphism in exon 20 of RYR1,
D20S220, and D20S47 (fig. 2). Relative order and ge-
netic distance (in cM) between markers within RYR1 is
D20S220-1-RYR1-0-D20S47 (Center for Medical Ge-
netics, Marshfield Medical Research Foundation). Al-
though an intragenic marker in RYR1 was not infor-
mative, two highly polymorphic microsatellite markers
tightly linked to RYR1 show cosegregation of different
alleles with GGA/RYR1 deletion, in each family. Thus,
each family has a unique haplotype associated with an
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Figure 3 A–C, Distribution of in vitro electrically evoked contractions in skeletal muscle from groups that are MH negative (A), MH
positive plus (B), and MH positive with and/or without deletion (C). Individual fascicle responses were graphed in order of increasing contraction
tension (in g force). Not all individuals in MH-positive groups have been screened for deletion, which, therefore, may or may not be present.
To the right of the graphs, the percentages of total fascicles in given ranges of tension level are denoted. D, Distribution of isometric-twitch
force in fascicles 391, 573, and 46, forming, respectively, MH-negative (solid curve/filled circles), MH-positive (dotted curve/open circles), and
MH-positive-plus (dashed curve/triangles) phenotypes in RYR1. Force ranges are 0–2 g, 2–5 g, 5–10 g, 10–14 g, 14–28 g, and 28–38 g. Each
group has a bimodal distribution of twitch forces, with most MH-negative and MH-positive twitch forces occurring in the range of 2–14 g
and with the MH-positive-plus twitch forces showing a higher percentage of forces in the range of 14–28 g.
MH-positive phenotype and a GGA/RYR1 deletion,
which shows that the two families are unrelated. Among
76 contracture-phenotyped unrelated MH-susceptible
individuals, 4 members of two families were found to
have the 2347 deletion, accounting for a 2.6% incidence.
The presence of the 2347 deletion in two unrelated MH-
affected families increases the likelihood that this dele-
tion is a significant cause of MH. In addition, this de-
letion was not found among 148 normal chromosomes.
The phenotypic hallmark of all MH-positive members
of both families who have the 2347 deletion was unu-
sually large contraction tensions in the muscle fascicles.
We compared twitch-tension–value data between three
groups of individuals from our diagnostic center: MH
negative, MH positive with and/or without deletion, and
MH positive with deletion (MH positive plus). Not all
individuals in the group with the MH-positive phenotype
have undergone complete genetic screening and, there-
fore, may or may not have the deletion. Analyses of the
data show that contraction tension differs ( )P ! .001
among groups, with means  SD of g (8.0 6.7 np
), g ( ), and g (573 10.3 7.9 np 391 16.5 9.0 np
) among fascicles from subjects with an MH-negative,41
MH-positive, and MH-positive-plus phenotype, respec-
tively. The distributions of electrically evoked muscle-con-
traction tensions among these groups illustrate these dif-
ferences (fig. 3).
The RYR1 calcium-release channel is the main path-
way by which Ca is released from the sarcoplasmic
reticulum (SR) membrane to initiate contraction in skel-
etal muscle. The reverse of this is muscle relaxation, via
both inactivation (closure) of the channel and ATP-de-
pendent pumping of calcium back into the SR. RYR1
mutations with linkage to MH are thought to cause an
abnormal opening of the calcium-release channel when
it is exposed to certain anesthetic drugs (Tong et al.
1997). With the exception of patients with RYR1 mu-
tations associated with central core disease (MIM
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117000), the majority of patients with MH show no
clinical manifestations of the mutation until the muscle
is exposed to anesthetic drugs. Studies on the contraction
kinetics of isolated human-MH skeletal muscle have not
revealed any abnormalities, in the absence of drugs
(Etchrivi 1998). It may be that the MH phenotype is
expressed only in the presence of drugs. The glutamic
acid deletion at position 2347 in RYR1 may have pro-
duced an RYR1 defect that is detected in the absence of
drugs. All four individuals with the 2347 deletion had
in vitro electrically evoked muscle contractions that were
unusually large and that were significantly different from
contraction tensions in muscle from MH-susceptible and
MH-insusceptible individuals. This finding may be a
hallmark of an MH muscle response, in the absence of
drug effects, that distinguishes the individual’s suscep-
tibility to MH.
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